1. Home
  2. LXEO vs FLGT Comparison

LXEO vs FLGT Comparison

Compare LXEO & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$6.84

Market Cap

731.3M

Sector

N/A

ML Signal

HOLD

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$14.65

Market Cap

867.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEO
FLGT
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.3M
867.4M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
LXEO
FLGT
Price
$6.84
$14.65
Analyst Decision
Strong Buy
Buy
Analyst Count
10
3
Target Price
$18.60
$28.33
AVG Volume (30 Days)
644.7K
486.9K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
75.08
N/A
EPS
N/A
N/A
Revenue
$654,000.00
$18,730,000.00
Revenue This Year
N/A
$10.66
Revenue Next Year
N/A
$12.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$13.46
52 Week High
$10.99
$31.04

Technical Indicators

Market Signals
Indicator
LXEO
FLGT
Relative Strength Index (RSI) 44.15 20.89
Support Level $6.15 N/A
Resistance Level $7.72 $19.96
Average True Range (ATR) 0.43 0.99
MACD 0.11 -0.83
Stochastic Oscillator 57.00 9.87

Price Performance

Historical Comparison
LXEO
FLGT

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Share on Social Networks: